Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Rhythm Pharmaceuticals (RYTM) over the last 10 years, with Q3 2025 value amounting to -$26.6 million.

  • Rhythm Pharmaceuticals' Cash from Operations fell 558.0% to -$26.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$109.1 million, marking a year-over-year increase of 1228.61%. This contributed to the annual value of -$113.9 million for FY2024, which is 1636.2% up from last year.
  • Per Rhythm Pharmaceuticals' latest filing, its Cash from Operations stood at -$26.6 million for Q3 2025, which was down 558.0% from -$23.3 million recorded in Q2 2025.
  • In the past 5 years, Rhythm Pharmaceuticals' Cash from Operations registered a high of -$18.8 million during Q4 2024, and its lowest value of -$53.6 million during Q1 2022.
  • Its 5-year average for Cash from Operations is -$34.7 million, with a median of -$34.0 million in 2022.
  • Its Cash from Operations has fluctuated over the past 5 years, first crashed by 5994.75% in 2022, then surged by 3774.66% in 2023.
  • Quarter analysis of 5 years shows Rhythm Pharmaceuticals' Cash from Operations stood at -$40.5 million in 2021, then increased by 15.99% to -$34.0 million in 2022, then increased by 13.58% to -$29.4 million in 2023, then skyrocketed by 35.86% to -$18.8 million in 2024, then tumbled by 41.27% to -$26.6 million in 2025.
  • Its Cash from Operations was -$26.6 million in Q3 2025, compared to -$23.3 million in Q2 2025 and -$40.4 million in Q1 2025.